Mumbai-based pharmaceutical giant Lupin Limited is making waves in the stock market after launching Rivaroxaban Tablets USP, 2.5 mg, in the United States. The announcement led to a nearly 3% rise in the company’s share price, reflecting strong investor confidence.
Rivaroxaban, the generic version of Xarelto® by Janssen Pharmaceuticals, is an anticoagulant designed to prevent blood clots, strokes, and other major cardiovascular events. The medication is widely used by patients suffering from coronary artery disease (CAD) and peripheral artery disease (PAD), making it a valuable addition to Lupin’s expanding portfolio.
With annual U.S. sales for this drug estimated at a massive $446 million, Lupin’s entry into this market is expected to be a significant revenue driver. The company’s stock responded positively, climbing 2.6% to a high of ₹2,081.95 on the Bombay Stock Exchange (BSE). Investors are optimistic that this move will strengthen Lupin’s foothold in the competitive U.S. pharmaceutical space.
About Lupin
Lupin is one of India’s leading drugmakers, operating across more than 100 countries. The company specializes in branded and generic medications, with a strong focus on cardiovascular, respiratory, and central nervous system treatments. With 15 manufacturing sites and seven research centers worldwide, Lupin continues to be a key player in the global pharmaceutical industry.
The latest launch further cements Lupin’s position in the high-demand cardiovascular segment, offering a cost-effective alternative to existing treatments. As the company continues to expand in the U.S. market, investors and analysts will be closely watching its next moves.
